News

A team led by Dr. Stephan Züchner at the University of Miami has discovered a new type of Charcot-Marie-Tooth (CMT) disease that may be treatable with drugs already approved for other diseases.

The CMTA Board of Directors approved a $265,000 research project for CMT2E that aims to advance CMT2E gene therapy by demonstrating positive results for axonal forms of CMT affecting motor neurons.

In a world turned upside down, The CMTA Report continues to bring you help for today and hope for tomorrow. In this issue you’ll find helpful stories on tendon transfers, HNPP and nerve conduction studies, as well as hopeful news ...

The CMTA Board of Directors approved a new research project aimed at developing biomarkers for CMT1B to aid in the collection of natural history data critical to clinical trials.

The CMTA is aware that the coronavirus (COVID-19) may have more of an impact on people and families who are at higher risk of infection, so we are reaching out to share resources and ensure you are informed.